Last reviewed · How we verify

Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab

German CLL Study Group · Phase 2 active Small molecule

Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab is a Small molecule drug developed by German CLL Study Group. It is currently in Phase 2 development. Also known as: Mabcampath, Fludarabine, Endoxan, Novantron.

At a glance

Generic nameFludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab
Also known asMabcampath, Fludarabine, Endoxan, Novantron
SponsorGerman CLL Study Group
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab

What is Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab?

Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab is a Small molecule drug developed by German CLL Study Group.

Who makes Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab?

Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab is developed by German CLL Study Group (see full German CLL Study Group pipeline at /company/german-cll-study-group).

Is Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab also known as anything else?

Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab is also known as Mabcampath, Fludarabine, Endoxan, Novantron.

What development phase is Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab in?

Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab is in Phase 2.

Related